(a) * * * (9) For the second and each subsequent performance year during the term of the agreement period, the ACO's benchmark is adjusted for the following, as applicable: For the addition and removal of ACO participants or ACO providers/suppliers in accordance with 425.118(b), for a change to the ACO's beneficiary assignment methodology selection under 425.226(a)(1), for a change to the beneficiary assignment methodology specified in subpart E of this part, for changes in values used in benchmark calculations as a result of issuance of a revised initial determination under 425.315, and for changes in values used in benchmark calculations as a result of the performance year being affected by significant, anomalous, and highly suspect billing under 425.672
General Laws c.94C 34A, this statute reinforces the states broader commitment to harm reduction and responsible drug testing practices
So there seems to be a nexus there, Levy said
Structure and function of neuronal nicotinic acetylcholine receptors
Other Payer Advanced APM determinations: Payer-Initiated and Eligible Clinician-initiated processes
3 FREE SHIPPING Every order ships free to the US.